ALMS: the cash flow

MyFinsight

For the year ending 2025-12-31, ALMS had -$79,579K decrease in cash & cash equivalents over the period. -$370,176K in free cash flow.

Cash Flow	2025-12-31
Net loss	-243,325
Stock-based compensation	43,524
Net accretion of discounts on marketable securities	-5,298
Depreciation and amortization	3,496
Non-cash lease expense	1,701
Gain on bargain purchase in connection with the acelyrin merger	187,907
Impairment of long-lived assets	529
Research and development prepaid expenses	-11,473
Other prepaid expenses and other assets	-17,229
Other assets, non-current	5,535
Accounts payable	-6,036
Deferred revenue	4,069
Research and development accrued expenses	2,087
Other accrued expenses and current liabilities	6,036
Operating lease liabilities	-3,212
Other liabilities, non-current	207
Deferred income tax liability	8,561
Net cash used in operating activities	-369,523
Maturities of marketable securities	447,955
Purchases of marketable securities	209,167
Purchases of property and equipment	653
Cash, cash equivalents and restricted cash acquired in connection with the acelyrin merger	49,742
Net cash provided by (used in) investing activities	287,877
Proceeds from issuance of common stock upon exercise of stock options	489
Repurchase of common stock shares issued upon early exercised restricted common stock	17
Proceeds from issuance of common stock under the 2024 espp	1,595
Net cash provided by financing activities	2,067
Net (decrease) increase in cash, cash equivalents and restricted cash	-79,579
Cash, cash equivalents and restricted cash at beginning of period	170,632
Cash, cash equivalents and restricted cash at end of period	91,053

Unit: Thousand (K) dollars (except for numbers of shares and EPS).